Strides Pharma Science Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: STAR BSE: 532531

₹1120.00

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #43 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Strides Pharma Science Limited (this stock)	10,323	42.5	18.2%	36.7%	0.45%	60	51	49

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹11,455 Cr

EV / EBITDA

24.0x

EV / Sales

5.06x

Market cap / Sales

4.56x

Earnings yield

2.36%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 584 Cr, up 16.7% YoY.

↑ Positive

Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 73 Cr, up 446.4% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	583	85	73	₹7.9100
March 31, 2026	606	27	16	₹1.7700
Dec. 31, 2025	554	135	122	₹13.2200
Sept. 30, 2025	522	25	32	₹3.4800
June 30, 2025	499	16	13	₹1.4500
March 31, 2025	556	28	16	₹1.7500
Dec. 31, 2024	551	21	15	₹1.6200
Sept. 30, 2024	610	14	15	₹1.6600
June 30, 2024	555	6	4	₹0.4300
March 31, 2024	618	53	54	₹5.8400
Dec. 31, 2023	520	4	3	₹0.2800
Sept. 30, 2023	540	4	1	₹0.1400
June 30, 2023	475	9	8	₹0.8900

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	584	610	657	536	500	568	553	634	567	647	529	563	487
Operating revenue	583	606	554	522	499	556	551	610	555	618	520	540	475
Other income	1	4	103	14	2	12	2	24	12	30	9	22	12
Operating expenses	522	531	472	460	431	488	477	547	494	527	454	497	420
Operating profit	61	74	81	62	67	68	74	63	61	91	66	43	56
Operating profit margin	10.5%	12.3%	14.7%	11.9%	13.5%	12.2%	13.4%	10.3%	11.0%	14.7%	12.6%	8.0%	11.7%
Depreciation	26	25	22	22	22	22	21	22	20	21	21	21	21
Interest	29	27	27	29	30	29	34	50	47	47	44	40	37
Exceptional items, gain / (loss)	76	—	—	—	—	—	-0	-0	—	-0	-5	—	—
Profit before tax	85	27	135	25	16	28	21	14	6	53	4	4	9
Tax	12	10	13	-7	3	12	6	-1	2	-1	1	3	1
Net profit	73	16	122	—	13	16	15	15	4	54	3	1	8
EPS	7.91	1.77	13.22	3.48	1.45	1.75	1.62	1.66	0.43	5.84	0.28	0.14	0.89
Net profit (TTM)	—	—	—	—	60	50	88	75	61	65	74	84	79
EPS (TTM)	26.38	19.92	19.90	8.30	6.48	5.46	9.55	8.21	6.69	7.15	8.22	9.33	8.75

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	2,180	203	184
March 31, 2025	2,139	78	2,886
March 31, 2024	2,153	70	65
March 31, 2023	1,854	-65	5

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	5.9%	3.5%	2,303^†	2,189^†	2,226^†	1,939^†	2,102^†	1,942^†	1,774^†	1,652^†	2,003^†	2,310^†
Operating revenue	5.5%	3.4%	2,180	2,139	2,153	1,854	1,979^†	1,848^†	1,674^†	1,537^†	1,812^†	2,134^†
Other income	—	—	123^†	50^†	72^†	84^†	123^†	93^†	100^†	115^†	191^†	176^†
Operating expenses	—	—	1,895^†	2,005^†	1,898^†	1,756^†	1,902^†	1,657^†	1,464^†	1,398^†	1,654^†	1,769^†
Operating profit	42.5%	8.3%	285^†	134^†	255^†	98^†	77^†	191^†	210^†	139^†	158^†	365^†
Operating profit margin	—	—	13.1%^†	6.3%^†	11.9%^†	5.3%^†	3.9%^†	10.3%^†	12.5%^†	9.0%^†	8.7%^†	17.1%^†
Depreciation	—	—	91^†	86^†	85^†	94^†	104^†	98^†	92^†	83^†	110^†	127^†
Interest	—	—	114^†	161^†	168^†	139^†	74^†	65^†	67^†	54^†	106^†	115^†
Exceptional items, gain / (loss)	—	—	0^†	-0^†	-5^†	-15^†	0^†	0^†	0^†	-4^†	-10^†	-78^†
Profit before tax	—	10.8%	203	78	70	-65	22^†	121^†	152^†	113^†	122^†	135^†
Tax	—	—	19^†	20^†	4^†	-69^†	-159^†	35^†	40^†	-1^†	-5^†	15^†
Net profit	239.8%	16.3%	184	2,886	65	5	180^†	86^†	112^†	—	—	—
EPS	246.2%	15.6%	19.92^†	5.46^†	7.15^†	0.48^†	20.06^†	9.64^†	12.47^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Operating margin	13.1%^†	6.3%^†	11.9%^†	5.3%^†	3.9%^†	10.3%^†	12.5%^†	9.0%^†	8.7%^†	17.1%^†
EBIT margin	14.5%^†	11.2%^†	11.0%^†	4.0%^†	4.8%^†	10.1%^†	13.1%^†	10.9%^†	12.6%^†	11.7%^†
PBT margin	9.3%	3.6%	3.2%	-3.5%	1.1%^†	6.6%^†	9.1%^†	7.4%^†	6.7%^†	6.3%^†
Net margin	8.4%	134.9%	3.0%	0.3%	9.1%^†	4.7%^†	6.7%^†	—	—	—
Interest coverage	2.79x^†	1.49x^†	1.41x^†	0.53x^†	1.29x^†	2.86x^†	3.28x^†	3.09x^†	2.15x^†	2.17x^†
Dividend payout	20.1%^†	45.8%^†	21.0%^†	0.0%^†	12.5%^†	20.7%^†	120.3%^†	—	—	—
Earnings retention	79.9%^†	54.2%^†	79.0%^†	100.0%^†	87.5%^†	79.3%^†	-20.3%^†	—	—	—
Current ratio	1.29x	1.32x	—	—	—	—	—	—	—	—
Quick ratio	0.97x	1.05x	—	—	—	—	—	—	—	—
Debt to equity	0.35x	0.36x	—	—	—	—	—	—	—	—
Return on equity	5.6%	90.4%	—	—	—	—	—	—	—	—
Return on assets	3.4%	57.4%	—	—	—	—	—	—	—	—
Return on capital employed	8.9%^†	7.0%^†	—	—	—	—	—	—	—	—
Asset turnover	0.40x	0.43x	—	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	278	-69	-199	169	109
March 31, 2025	421	-138	-370	166	255
March 31, 2024	-36	-61	108	67	-103
March 31, 2023	242	-183	11	81	161
March 31, 2022	-283	19	251	68	-351

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	5,396	3,284	3,191	975	173	2,374	1,840	16	634	580
March 31, 2025	5,031	3,193	3,101	1,029	127	2,146	1,630	6	606	432
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.